

Docket No.: 710A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Nicholas J. Papadopoulos et al.

Serial No.: 10/009,852 **Group:** 1647

Filing Date: December 6, 2001 **Examiner:** Hunnicutt, Rachel K.

Title: Modified Chimeric Polypeptides with Improved Pharmacokinetic Properties and Methods of Making and Using Thereof

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 and 1.97**

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450.

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed before the mailing date of any or a final action under § 1.113, a notice of allowance under § 1.311, or any action that otherwise closes prosecution in the application. Accordingly, this IDS is accompanied by the fee set forth in 37 CFR § 1.17(p).

Fees

The fee required for the filing of this Information Disclosure Statement is estimated to be \$180.00. Applicants hereby authorize such charge to Deposit Account number 18-0650. If any additional fee should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-0650.

Respectfully submitted



Valeta Gregg
Reg. No. 35,127
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant : Nicholas J. Papadopoulos et al.
Serial No. : 10/009,852
Date Filed : December 6, 2001
For : Modified Chimeric Polypeptides with
Improved Pharmacokinetic Properties
and Methods of Making and Using
Thereof
Examiner : Hunnicutt, Rachel K.
Group Art Unit : 1647

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

OTHER DOCUMENTS

Examiner
Initials

- ____ Holash, J., et al. (2002) PNAS, Vol. 99, No. 17, pp. 11393-11398.
- ____ Heidaran, M.A., (1990) The Journal of Biological Chemistry, Vol. 265, No. 31, Issue of November 5, pp. 18741-18744.
- ____ Cunningham, S.A. et al., (1997) Biochemical and Biophysical Research Communications, Vol. 231, pp.596-599.
- ____ Fuh, G. et al. (1998) The Journal of Biological Chemistry, Vol. 273, No. 18, Issue of May 1, pp. 11197-11204.
- ____ Wiesmann, C. et al. (1997) Cell, Vol. 91, pp. 695-704.
- ____ Barleon, B. et al. (1997) The Journal of Biological Chemistry, Vol. 272, No. 16, pp. 10382-10388.


710A-US
U.S. Serial No. 10/009,852
PTO 1449 Form
Papadopoulos et al.
Page 2

Davis-Smyth, T. et al. (1998) The Journal of Biological Chemistry, Vol.
273, No. 6, pp. 3216-3222.

EXAMINER
CONSIDERED

DATE

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,
By: 
Valeta Gregg
Reg. No. 35,127
Attorneys for Applicant
Patent Agent for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400